NEW YORK (GenomeWeb News) – Sigma-Aldrich said after the close of the market Tuesday that it has completed the acquisition of BioReliance Holdings for $350 million in cash.
It purchased the firm from Avista Capital Partners, which had acquired BioReliance nearly five years ago from Invitrogen, now part of Life Technologies, for $210 million.
Rockville, Md.-based BioReliance provides biologic, specialized toxicology, and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers. The firm had full-year 2010 revenues of around $110 million and is expected to post double-digit growth for 2011.
BioReliance will become part of SAFC, the custom manufacturing and services business unit of Sigma-Aldrich.
"By leveraging SAFC's industrial media presence and BioReliance's biological testing services, we can provide new and better end-to-end product solutions and services to our biopharmaceutical customers," SAFC President Gilles Cottier, said in a statement. "The alliance also provides an opportunity to leverage our CompoZr zinc finger nuclease technology with BioReliance's Toxicology and Animal Health Services operations for the development of new assays, cell lines and animal models for the Research marketplace."